MGTX MeiraGTx Holdings plc Ordinary Shares
XNAS
9.21
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MGTX
$9.21
—
Key stats
$9.21
- 52-Week Range
- $6.62 – $15.35
- YTD
- +17.86%
- IV Rank (30D)
- 100.0
- Straddle Price
- $5.30
- P/C Vol Ratio
- 3.20
- Market Cap
- $0.9B
- Open
- $9.70
- Day Range
- $9.08 – $9.72
- Volume
- 596,705
- Prev Close
- $9.77
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 1.39 |
| Cost of Equity (CAPM) | 12.75% (VRP-adj) |
| WACC | 12.37% |
| Volatility Risk Premium | +117.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 36.6% |
| Book / Price | -7.4% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 13.1% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $12.25 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $10.35 |
| Bollinger Width / SMA20 | 219.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: BTSG, CDNA, CON, HAE, HRMY, KRYS, OPCH, VCEL
60-Day Conviction
4%
20-Day Fair Value
≈ by Nov 23, 2026
$9.17
α -0.4%
rank 25%
conviction
29%
40-Day Fair Value
≈ by Dec 22, 2026
$9.36
α +1.6%
rank 32%
conviction
51%
60-Day Fair Value
≈ by Jan 20, 2027
$9.22
α +0.1%
rank 25%
conviction
4%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $0.96 | 62% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.3× · 8 peers |
| Peer EV/EBITDA | n/a | 0% | median 20.4× · 8 peers |
| Peer P/B | n/a | 0% | median 6.2× · 8 peers |
| Peer P/S | $3.09 | 37% | median 3.1× · 8 peers |
| Market Anchor (SMA50) | $12.25 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $8.16 | 0% | 7 strikes · skew +0.90 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 393
- List Date
- 2018-06-08
- CIK
- 0001735438
- Next Earnings
- 2026-11-12 (After-Close)
- EPS Forecast
- ($0.46) (4 est.)
- Headquarters
- New York, NY
- Homepage
- https://www.meiragtx.com
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to en…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -7.73% | -35.89% | 29.01% | -17.19% | 0.32% | -2.56% | -5.67% |
| Feb | -3.76% | -3.63% | -7.88% | 0.98% | 16.31% | -3.45% | -0.24% |
| Mar | -5.69% | -0.14% | -33.38% | -5.30% | 4.63% | 14.25% | -4.27% |
| Apr | 6.17% | -27.69% | -11.57% | -16.01% | 15.10% | 1.43% | -5.43% |
| May | -4.24% | -18.86% | 26.01% | -1.80% | -29.48% | 13.18% | -2.53% |
| Jun | 5.23% | -6.54% | -2.47% | -14.78% | 19.41% | 37.86% | 6.45% |
| Jul | -12.56% | 9.38% | -6.39% | 27.56% | 18.06% | -7.42% | 4.77% |
| Aug | -8.15% | 4.67% | 3.62% | -16.60% | -4.58% | 16.25% | -0.80% |
| Sep | 4.44% | -2.77% | -22.92% | 6.65% | 12.74% | -22.48% | -4.06% |
| Oct | 61.53% | -11.56% | -2.80% | 33.49% | 9.79% | -13.60%* | 12.81% |
| Nov | -14.17% | -15.73% | 3.57% | 16.52% | -4.93% | -- | -2.95% |
| Dec | 34.43% | 3.33% | 30.48% | -8.28% | 1.40% | -- | 12.27% |
| Total | 40.07% | -71.00% | -15.50% | -9.90% | 59.06% | 22.62% | 4.22% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.27
SMA 50: $12.18
SMA 200: $10.25
Current: $9.21
EMA 12: $9.91
EMA 26: $10.63
MACD: -0.7187 | Signal: 0.0124
BEARISH
ADX (14): 36.51
TREND
+DI: 11.68
−DI: 30.86
Momentum Oscillators
RSI (14): 32.19
NEUTRAL
Stoch %K: 23.53
Stoch %D: 27.35
Williams %R: -93.26
Volume & Volatility
BB Upper: $11.51
BB Lower: $9.02
NEUTRAL
OBV: 7,867,540
Vol SMA 20: 905,596
Vol ROC: 13.75%
ATR: $0.57
True Range: $0.69
HV 20: 54.0%
HV 30: 51.6%
HV 60: 47.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report
System Prompt: Analyze the stock data of MeiraGTx (MGTX) and provide a comprehensive report.
Executive Summary: Overall assessment: NEUTRAL with confidence level 6/10 Key drivers: Recent positive news headlines, strong momentum signals, and beta analysis Primary risks: High volatility, potential market rotation, and regulatory uncertainty
Investment thesis: MGTX has significant growth potential due to its innovative gene therapy pipeline and partnerships. However, the stock is highly volatile, and investors should be cautious of potential market rotation and regulatory changes.
Recent news sentiment impact: The recent positive news headlines have contributed positively to the stock's performance, with a strong correlation between the news sentiment and the stock price.
Technical Analysis:
- Trend Direction: Short-term: Uptrend (1-4 weeks), Medium-term: Neutral (1-3 months), Long-term: Bullish (3-12 months)
- Support/Resistance Levels: Key levels include the SMA 20 ($10.20) and SMA 50 ($9.86) as key support, while the upper Bollinger Band ($12.26) serves as resistance.
- Momentum Signals:
- RSI interpretation: Overbought (71.98), indicating potential for a pullback or consolidation
- MACD signal: Bullish, with a strong momentum signal indicating continued upward movement
- Bollinger Bands position: Neutral, with the price near the middle band and volatility relatively low
- Volume Analysis: Volume trends indicate increasing interest in the stock, with institutional participation supporting the recent price move.
News & Sentiment Analysis:
- Recent Headlines Summary: The headlines suggest a mix of positive and negative news, with recent partnerships and acquisitions contributing to the stock's growth.
- Sentiment Assessment: Overall sentiment is positive, with 3 out of 6 headlines having a positive tone.
- Catalyst Identification: Upcoming earnings reports and regulatory approvals for gene therapy products could drive future price movements.
- Market Narrative: The news aligns with the technical signals, suggesting continued upward movement if the momentum signals remain strong.
Risk & Volatility Assessment:
- Beta Interpretation: MGTX has a high beta (1.80) relative to the market, indicating high volatility and potential for significant price movements.
- Volatility Regime: Current volatility is relatively low compared to historical levels.
- Options Market Signals: IV rank is low (17.6%), suggesting that options market is not pricing in extreme volatility. Put/call ratios indicate a bullish sentiment.
- Downside Protection: Support levels include the SMA 20 and SMA 50, while the upper Bollinger Band serves as resistance.
Market Context & Positioning:
- Sector Performance: The biotech sector has been performing well, with MGTX benefiting from this trend.
- Institutional Activity: Institutional participation has increased in recent weeks, supporting the stock's price movement.
- Correlation Analysis: MGTX has a high correlation (0.38) with the market, indicating that it is influenced by broader market trends.
- Relative Valuation: The stock is trading within its historical range and is relatively undervalued compared to peers.
Key Levels & Action Items:
- Critical Price Levels: SMA 20 ($10.20) and SMA 50 ($9.86) as key support, while the upper Bollinger Band ($12.26) serves as resistance.
- Breakout/Breakdown Levels: The upper Bollinger Band could trigger a breakout above $12.26, while a breakdown below $9.86 could lead to further declines.
- Time-Sensitive Catalysts: Upcoming earnings reports and regulatory approvals for gene therapy products could drive future price movements.
- Risk Management: Stop-loss levels should be set near the SMA 20 and SMA 50, with position sizing considering the high volatility.
Conclusion: MGTX has strong momentum signals and a positive news sentiment, which could support continued upward movement. However, the stock's high volatility and beta suggest that investors should be cautious of potential market rotation and regulatory changes. A balanced approach to risk management and technical analysis is recommended to navigate the complexities of this stock.
Generated
News
All MGTX news →
Earnings History
15 of 16 under expected move
Avg Expected Move
26.02%
Avg Actual Move
4.02%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-11 | After-Close | 17.24% | 1.99% | 0.12x | Within |
| 2021-11-10 | After-Close | 13.81% | 3.23% | 0.23x | Within |
| 2022-11-10 | After-Close | 28.30% | 3.73% | 0.13x | Within |
| 2023-03-14 | After-Close | 3.20% | 5.12% | 1.60x | Exceeded |
| 2023-05-11 | After-Close | 17.67% | 1.03% | 0.06x | Within |
| 2023-11-14 | After-Close | 5.79% | 2.27% | 0.39x | Within |
| 2024-03-14 | After-Close | 18.31% | 7.63% | 0.42x | Within |
| 2024-08-12 | After-Close | 77.50% | 5.50% | 0.07x | Within |
| 2024-11-13 | Pre-Market | 43.92% | 5.71% | 0.13x | Within |
| 2025-03-13 | After-Close | 34.55% | 5.58% | 0.16x | Within |
| 2025-05-13 | After-Close | 44.17% | 10.00% | 0.23x | Within |
| 2025-08-14 | After-Close | 17.41% | 1.92% | 0.11x | Within |
| 2025-11-13 | After-Close | 11.50% | 0.85% | 0.07x | Within |
| 2026-03-26 | Pre-Market | 41.67% | 1.18% | 0.03x | Within |
| 2026-05-12 | After-Close | 12.00% | 1.84% | 0.15x | Within |
| 2026-08-13 | After-Close | 29.20% | 6.71% | 0.23x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MGTX Options Activity & IV Rank
MGTX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 236.5%
7-DTE IV: —
Expected Move: $5.30
7-DTE Move: $5.30
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 44
Put Volume: 141
P/C Volume: 3.205
BEARISH
Call OI: 54
Put OI: 201
P/C OI: 3.722
Total OI: 255
ATM Options Pricing
ATM Call: $2.55
ATM Put: $2.75
Call %: 27.7%
Put %: 29.9%
Chain Summary
Chain Volume: 802
Chain OI: 909
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 35th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
35%
vs own history
GEX tilt
+0.36
OI-weighted, today
Vanna tilt
+0.37
δ-sensitivity to IV
Charm tilt
-0.67
δ-decay vs time
Vanna tilt +0.37: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.67: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 23 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 23 · ATM 251.4% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)100.0HighOct 23
Straddle Price (30 DTE)$5.30Oct 23
Beta Analysis
Risk Metrics
Beta: 1.5964
Alpha: 0.73%
Correlation: 0.3511
R-Squared: 12.3%
Stock Volatility: 58.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own MGTX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $40.1M | #725 of 3716 | -14.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $8.8M | #1681 of 6285 | +460.8% | 13F | |
| Point72 Hedge fund Steve Cohen | $2.7M | #1180 of 1945 | +185.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $92K | #3029 of 4729 | +2.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MGTX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 80,816,114 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$1.13M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | J. Goldman & Co LP | $1.12M | 99.34% | 2026-06-30 |
| 2 | DIADEMA PARTNERS LP | $6.75K | 0.60% | 2026-06-30 |
| 3 | Persistent Asset Partners Ltd | $690 | 0.06% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
MGTX Insider Trading (Form 4)
Latest: 2026-10-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Richard Giroux | CFO & COO | Sell (S) | −56,000 | $9.95 | -$557.2K | EDGAR |
| 2026-10-06 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Sell (S) | −27,659 | $10.64 | -$294.3K | EDGAR |
| 2026-09-24 | Alan Sebulsky | Director | Grant (A) | +100,000 RSU | — | EDGAR | |
| 2026-08-18 | Alexandria Forbes | PRESIDENT & CEO | Sell (S) | −62,000 | $13.86 | -$859.3K | EDGAR |
| 2026-07-21 | Richard Giroux | CFO & COO | Sell (S) | −56,000 | $12.51 | -$700.6K | EDGAR |
| 2026-07-07 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Sell (S) | −27,659 | $14.80 | -$409.5K | EDGAR |
| 2026-06-29 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | Grant (A) | +100,000 RSU | — | EDGAR | |
| 2026-06-29 | Alexandria Forbes | PRESIDENT & CEO | Grant (A) | +980,000 RSU | — | EDGAR | |
| 2026-06-29 | Robert K Zeldin | CHIEF MEDICAL OFFICER | Grant (A) | +100,000 RSU | — | EDGAR | |
| 2026-06-29 | Richard Giroux | CFO & COO | Grant (A) | +980,000 RSU | — | EDGAR | |
| 2026-06-29 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | Grant (A) | +70,000 RSU | — | EDGAR | |
| 2026-06-15 | Keith R. Harris | Director | Grant (A) | +106,441 RSU | — | EDGAR | |
| 2026-06-15 | Neil Mendoza | Director | Grant (A) | +66,641 RSU | — | EDGAR | |
| 2026-06-15 | Nicole Seligman | Director | Grant (A) | +60,000 RSU | — | EDGAR | |
| 2026-06-15 | Ellen Hukkelhoven | Director | Grant (A) | +60,000 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MGTX Insider Holdings
10 insiders · @ $9.21
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | Director | 11,281,103 | $103.90M | $178.27M | 9 | 2026-06-15 |
| 2 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 10,786,658 | $99.35M | $62.28M | 4 | 2026-04-23 |
| 3 | Alexandria Forbes | PRESIDENT & CEO | 1,354,680 | $12.48M | -$7.49M | 37 | 2026-08-18 |
| 4 | Richard Giroux | CFO & COO | 937,530 | $8.63M | -$3.91M | 33 | 2026-10-20 |
| 5 | Stuart Naylor | CHIEF SCI OFCR, OPHTHALMOLOGY | 613,187 | $5.65M | -$2.61M | 35 | 2026-10-06 |
| 6 | Keith R. Harris | Director | 200,000 | $1.84M | $0 | 11 | 2026-06-15 |
| 7 | Thomas E Shenk | Director | 157,476 | $1.45M | -$200.0K | 11 | 2026-06-15 |
| 8 | Robert K Zeldin | CHIEF MEDICAL OFFICER | 146,204 | $1.35M | $39.5K | 18 | 2026-06-29 |
| 9 | Robert J Wollin | GENERAL COUNSEL AND SECRETARY | 57,377 | $528.4K | $7.9K | 16 | 2026-06-29 |
| 10 | Nicole Seligman | Director | 5,000 | $46.1K | $81.5K | 9 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MGTX Board & Officers
As of SEC filings through Oct 20, 2026Directors 11
- Alexandria Forbes · since Jun 8, 2018
- Ellen Hukkelhoven · since Jun 8, 2018
- Keith R. Harris · since Jun 8, 2018
- Neil Mendoza · since Jun 8, 2018
- Perceptive Advisors LLC (entity) · since Jun 8, 2018
- Perceptive Life Sciences Master Fund Ltd (entity) · since Jun 8, 2018
- Thomas E Shenk · since Jun 8, 2018
- Nicole Seligman · since May 9, 2019
- Joseph Edelman · listed since Nov 2020
- Debra Yu · since Apr 25, 2022
- Alan Sebulsky · since Sep 23, 2026
Officers 6
- Alexandria Forbes · President & CEO · since Jun 8, 2018
- Richard Giroux · CFO & COO · listed since Jan 2020
- Robert K Zeldin · Chief Medical Officer · since Aug 3, 2020
- Penny Renee Fleck · Chief Development Officer · since May 11, 2026
- Stuart Naylor · Chief Sci Ofcr, Ophthalmology · listed since Jun 2026
- Robert J Wollin · General Counsel and Secretary · since Jun 10, 2020
10% owners 3
- Joseph Edelman · since Jun 8, 2018
- Perceptive Advisors LLC (entity) · since Jun 8, 2018
- Perceptive Life Sciences Master Fund Ltd (entity) · since Jun 8, 2018
Changes in the last 10 years (38)
| Sep 23, 2026 | Alan Sebulsky became a director |
| Jun 29, 2026 | Stuart Naylor listed as Chief Sci Ofcr, Ophthalmology (previously Chief Dev. Officer) in SEC filings |
| May 11, 2026 | Penny Renee Fleck became Chief Development Officer |
| Aug 12, 2024 | Sanofi became a 10% owner |
| Sep 18, 2023 | Johnson & Johnson Innovation - JJDC, Inc. reported in an SEC filing no longer being a 10% owner |
| Apr 21, 2023 | The company announced the departure of Arnold J Levine from the board in an SEC filing |
| Jan 10, 2023 | Stuart Naylor listed as Chief Dev. Officer (previously Chief Development Officer) in SEC filings |
| Nov 9, 2022 | Johnson & Johnson Innovation - JJDC, Inc. became a 10% owner |
| Nov 9, 2022 | & Johnson Johnson became a 10% owner |
| Jun 27, 2022 | The company announced the departure of Joel S Marcus from the board in an SEC filing |
| Apr 25, 2022 | Debra Yu became a director |
| Nov 24, 2020 | Joseph Edelman first listed as a director in an SEC filing |
| Aug 3, 2020 | Robert K Zeldin became Chief Medical Officer |
| Jun 10, 2020 | Robert J Wollin became General Counsel and Secretary |
| Jan 10, 2020 | Stuart Naylor no longer listed as a director in SEC filings |
| Jan 10, 2020 | Richard Giroux listed as CFO & COO (previously Chief Operating Officer) in SEC filings |
| May 9, 2019 | Nicole Seligman became a director |
| Apr 1, 2019 | Bruce Gottlieb became General Counsel |
| Feb 19, 2019 | Martin Indyk became a director |
| Jan 2, 2019 | Stuart Naylor listed as Chief Development Officer (previously Chief Dev. Officer) in SEC filings |
| Oct 2, 2018 | Katherine Breedis became Chief Financial Officer |
| Jun 8, 2018 | Thomas E Shenk became a director |
| Jun 8, 2018 | Stuart Naylor became a director |
| Jun 8, 2018 | Stuart Naylor became Chief Dev. Officer |
| Jun 8, 2018 | Richard Giroux became Chief Operating Officer |
| Jun 8, 2018 | Perceptive Life Sciences Master Fund Ltd became a director |
| Jun 8, 2018 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Jun 8, 2018 | Perceptive Advisors LLC became a director |
| Jun 8, 2018 | Perceptive Advisors LLC became a 10% owner |
| Jun 8, 2018 | Neil Mendoza became a director |
| Jun 8, 2018 | Keith R. Harris became a director |
| Jun 8, 2018 | Joseph Edelman became a 10% owner |
| Jun 8, 2018 | Joel S Marcus became a director |
| Jun 8, 2018 | Gregory S. Moss became a director |
| Jun 8, 2018 | Ellen Hukkelhoven became a director |
| Jun 8, 2018 | Arnold J Levine became a director |
| Jun 8, 2018 | Alexandria Forbes became a director |
| Jun 8, 2018 | Alexandria Forbes became President & CEO |
Not reported recently (6)
- Sanofi · Last reported as a 10% owner in an SEC filing dated Aug 13, 2024
- Martin Indyk · Last reported as a director in an SEC filing dated Jun 6, 2024
- & Johnson Johnson · Last reported as a 10% owner in an SEC filing dated Nov 14, 2022
- Bruce Gottlieb · Last reported as General Counsel in an SEC filing dated Apr 2, 2019
- Katherine Breedis · Last reported as Chief Financial Officer in an SEC filing dated Jan 2, 2019
- Gregory S. Moss · Last reported as a director in an SEC filing dated Jun 8, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MGTX Proposed Insider Sales (Form 144)
Latest: 2026-10-20
? Form 144 Guide
Last 30d:
2 filings
· $852K notice value
· Last 90d:
3 filings
· $1.7M notice value
· 3 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Alexandria Forbes (1, $859K) · Richard Giroux (1, $557K) · Naylor Stuart (1, $294K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-20 | Richard Giroux | Officer | 56,000 | $557.2K | 2026-10-20 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-10-06 | Naylor Stuart | Officer | 27,659 | $294.3K | 2026-10-06 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-18 | Alexandria Forbes | Officer, Director | 62,000 | $859.3K | 2026-08-18 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-21 | Richard Giroux | Officer | 56,000 | $700.6K | 2026-07-21 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-07 | Naylor Stuart | Officer | 27,659 | $368.7K | 2026-07-07 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-05-19 | Alexandria Forbes | Officer, Director | 62,000 | $568.5K | 2026-05-19 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-04-21 | Richard Giroux | Officer | 56,000 | $572.5K | 2026-04-21 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-04-07 | Naylor Stuart | Officer | 27,661 | $258.9K | 2026-04-07 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-24 | Alexandria Forbes | Officer, Director | 62,000 | $459.4K | 2026-03-24 | Merrill Lynch | 10b5-1 | EDGAR |
| 2025-10-21 | Richard Giroux | Officer | 24,000 | $212.9K | 2025-10-21 | Merrill Lynch | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
37 ETFs hold MGTX
25 shown · $50.46M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $14.6M | $74.2B | 2026-10-22 |
| 2 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.43% | $5.7M | $1.3B | 2026-10-23 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.05% | $5.4M | $10.7B | 2026-10-22 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.03% | $4.3M | $13.6B | 2026-10-22 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.8M | — | 2026-09-30 |
| 6 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.10% | $2.5M | $2.5B | 2026-10-22 |
| 7 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 0.60% | $2.1M | $358.1M | 2026-10-23 |
| 8 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.15% | $2.1M | $1.4B | 2026-10-23 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.9M | — | 2026-09-30 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.15% | $1.8M | $1.2B | 2026-10-22 |
| 11 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.1M | $13.9B | 2026-10-22 |
| 12 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.09% | $909,653 | $1.0B | 2026-10-23 |
| 13 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $672,148 | — | 2026-07-31 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.03% | $565,422 | — | 2026-09-30 |
| 15 | FAD First Trust Multi Cap Growth AlphaDEX® Fund | First Trust | 0.09% | $520,383 | $590.1M | 2026-10-23 |
| 16 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.03% | $503,350 | — | 2026-10-22 |
| 17 | GWX State Street® SPDR® S&P® International Small Cap ETF | SPDR (State Street) | 0.05% | $433,302 | $900.0M | 2026-10-22 |
| 18 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.04% | $414,649 | $1.1B | 2026-10-22 |
| 19 | RSSL Global X Russell 2000 ETF | Global X | 0.02% | $266,427 | — | 2026-10-23 |
| 20 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $173,496 | $20.3B | 2026-10-22 |
| 21 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $128,315 | — | 2026-09-30 |
| 22 | ISCG iShares Morningstar Small-Cap Growth ETF | iShares (BlackRock) | 0.01% | $127,235 | $952.3M | 2026-10-22 |
| 23 | VFQY Vanguard U.S. Quality Factor ETF | Vanguard | 0.02% | $113,332 | — | 2026-10-22 |
| 24 | GINN Goldman Sachs Innovate Equity ETF | Goldman | 0.04% | $73,744 | $176.9M | 2026-10-22 |
| 25 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.06% | $67,786 | — | 2026-10-24 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.48
TTM Revenue
$79.76M
TTM Net Income
$-120.53M
TTM Op. Cash Flow
$8.28M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $293.00K | $-46.31M | $-0.57 | $17.81M |
| Q4 '25 | 2025-12-31 | $75.36M | $15.09M | $0.19 | $46.63M |
| Q3 '25 | 2025-09-30 | $410.00K | $-50.51M | $-0.62 | $-12.21M |
| Q2 '25 | 2025-06-30 | $3.69M | $-38.80M | $-0.48 | $-43.95M |
| Q1 '25 | 2025-03-31 | $1.93M | $-39.98M | $-0.51 | $-36.83M |
| Q4 '24 | 2024-12-31 | $21.39M | $-39.40M | $-0.50 | $-23.28M |
| Q3 '24 | 2024-09-30 | $10.91M | $-39.33M | $-0.55 | $-25.02M |
| Q2 '24 | 2024-06-30 | $282.00K | $-48.62M | $-0.76 | $-19.46M |
| Q1 '24 | 2024-03-31 | $697.00K | $-20.44M | $-0.32 | $-36.74M |
| Q4 '23 | 2023-12-31 | $2.04M | $20.21M | $0.42 | $-14.55M |
| Q3 '23 | 2023-09-30 | $5.10M | $-44.30M | $-0.74 | $-24.41M |
| Q2 '23 | 2023-06-30 | $3.54M | $-29.58M | $-0.53 | $-29.01M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-14
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
9.33
EV/EBITDA
—
EV/Sales
9.06
ROE
—
ROA
-49.3%
Div Yield
0.00%
FCF Yield
1.11%
Debt/Equity
—
Current Ratio
—
Market Cap
$744.32M
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.00M
SI % of Float
10.05%
Days to Cover
5.04
Short Vol Ratio
57.1%
Free Float
59.64M
Float %
62.1%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-08-14